Analyst Says Levadex Data Could Lift MAP Stock

MAP Pharmaceuticals Inc. plans to share additional data from testing of its migraine drug candidate Levadex next week, and a Wedbush Morgan analyst said the results could boost MAP’s share price.
The Miami Herald